Sanofi's newly approved intradermal quadrivalent Fluzone forgoes the shot

The FDA approved Sanofi's ($SNY) Fluzone Intradermal Quadrivalent in adults ages 18 through 64. This addition to the company's flu vaccine portfolio is well received after last year's 94% surge in vaccine sales upon adding the quadrivalent contender to the mix. For those afraid of getting shots, Fluzone Intradermal might be an easier option. While it is administered directly into the skin, the microneedle is one-tenth the size of the typical needles used for intramuscular injection of flu vaccines. Story